Fax: (801) 585-0159
Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer†
Article first published online: 28 JUL 2006
Copyright © 2006 American Cancer Society
Volume 107, Issue 5, pages 1050–1054, 1 September 2006
How to Cite
Akerley, W., Safran, H., Zaner, K., Ready, N., Mega, T. and Kennedy, T. (2006), Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer. Cancer, 107: 1050–1054. doi: 10.1002/cncr.22095
Informed consent was obtained from the subjects and/or guardians.
- Issue published online: 21 AUG 2006
- Article first published online: 28 JUL 2006
- Manuscript Accepted: 6 JUN 2006
- Manuscript Revised: 11 APR 2006
- Manuscript Received: 29 DEC 2005
- Lilly Oncology (Raritan, NJ)
- Bristol-Myers Squibb (Princeton, NJ)
- lung cancer;
- weekly schedule;
The purpose of the current study was to evaluate the efficacy and tolerance of the noncisplatin-based combination of paclitaxel and gemcitabine administered weekly for patients with untreated metastatic nonsmall cell lung cancer (NSCLC).
Patients with Stage IIIB/IV or recurrent NSCLC, a performance status of 0–2, and no prior chemotherapy exposure were eligible. Patients received gemcitabine 1000 mg/m2 and paclitaxel 85 mg/m2 on Days 1, 8, 15, 22, 29, 36 of an 8-week cycle until progression.
Thirty-nine eligible patients were enrolled. The median age was 66 years and 14 patients were ≥70 years old. Performance status was 2 in 13 (33%) and 29 patients (75%) had Stage IV. Five patients (12.8%) developed interstitial pneumonitis and 2 of these were responsive to steroid therapy. The overall response rate was 23.1%, with no complete responses. The median survival was 32 weeks and the 1-year survival was 32%.
This regimen of weekly paclitaxel and gemcitabine has modest activity in advanced NSCLC. Cancer 2006. © 2006 American Cancer Society.